Eli Lilly (LLY) and Company announced that the European Commission has granted marketing authorization for Kisunla for the treatment of early symptomatic Alzheimer’s disease in adults with mild cognitive impairment as well as those with mild dementia stages of AD with confirmed amyloid pathology who are apolipoprotein E heterozygotes or non-carriers.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Eli Lilly (LLY) to Build $6.5 Billion Manufacturing Plant in Texas
- FDA approves Lilly’s Inluriyo for type of advanced or metastatic breast cancer
- Eli Lilly (LLY) Stops Trial of Drug Meant to Preserve Muscle Mass
- Eli Lilly’s New Study on LY3537031: A Potential Game-Changer?
- Eli Lilly’s Phase 1 Study of LY3876602: Key Insights for Investors